Reset trial dapt. In fact, only four randomized trial have prospectively compared 12 months of DAPT with a longer duration after DES placement (14 - 17). Jun 6, 2019 · In patients undergoing percutaneous coronary intervention, is 1 month of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy noninferior to 12 months of DAPT with aspirin and clopidogrel for adverse cardiovascular and bleeding events?In Overriding Concepts and Updated Recommendations for DAPT and Duration Decisions about treatment with and duration of DAPT require a thoughtful assessment of the benefit/risk ratio (ischemic and bleeding risk), integration of study data, and consideration of patient preference. Sep 19, 2012 · The investigators randomly assigned 2,117 patients with coronary artery stenosis into two groups according to DAPT duration and stent type: 3-month DAPT following Endeavor zotarolimus-eluting stent (E-ZES) implantation (E-ZES 3-month DAPT, n = 1,059) versus 12-month DAPT following the other DES implantation (standard therapy, n = 1,058). Jan 1, 2012 · Description: The goal of the trial was to evaluate treatment with a zotarolimus-eluting stent (Endeavor) and 3 months of dual antiplatelet therapy compared with other drug-eluting stent types and 12 months of dual antiplatelet therapy. 22 This was a multicenter, prospective registry designed to assess the incidence of thrombosis following second-generation DES implantation, which included 4768 patients; among these, 4354 were treated with 12 months of DAPT. The second controversial point in the report is the possible clinical benefit effect of prolonging DAPT up to 18 to 48 months. In the RESET (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation) trial, we compared the safety and efficacy between patients treated with E-ZES 3-month DAPT and patients treated with the stan-dard therapy. Background: There have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter duration DAPT after DES implantation. The study enrolled 1525 patients to 3 mo of DAPT followed by aspirin monotherapy after the XIENCE CoCr-EES and compared this to the CoCr-EES group in the RESET trial as a historical control, where 90% had DAPT at 12 mo. 09–9. 30 The RESET trial randomized 2,117 Korean patients into two groups according to DAPT duration and stent type, 3 months following Dec 4, 2014 · The Dual Antiplatelet Therapy (DAPT) study was an international, multicenter, randomized, placebo-controlled trial that was designed to determine the benefits and risks of continuing dual Nov 26, 2018 · Background We evaluated optimal duration of dual antiplatelet therapy (DAPT) after second-generation drug-eluting stent (DES) implantation in acute coronary syndrome (ACS). Sep 30, 2024 · After coronary stent implantation, prolonged dual antiplatelet therapy (DAPT) increases bleeding risk, requiring personalization of DAPT duration. Aug 18, 2015 · The RESET trial was the first study evaluating a mandatory DAPT duration of 3 months with a second-generation DES (35). Background There have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. As a result, discontinuation of clopidogrel 3 months after coronary intervention did not increase the risk of cardiac death, MI, or stent thrombosis at 1 year (hazard ratio [HR], 0. 90; 95% CI, 0. 02). As a historical control group, we selected the CoCr-EES group in the RESET (Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial) trial (a randomized controlled trial comparing CoCr-EES with sirolimus-eluting stent conducted by the same study group in 2010), where nearly 90 % of patients had continued DAPT at 1 year []. Mar 25, 2012 · CHICAGOThe zotarolimus eluting coronary stent (Endeavor, Medtronic) plus three months of dual-antiplatelet therapy (DAPT) could be safe and beneficial for selected patients with coronary artery disease who may need to stop DAPT soon after drug-eluting stent implantation, according to study results of RESET presented March 24 at the 61st annual American College of Cardiologys (ACC) scientific Dec 11, 2023 · Of note, while many trials have examined short-term DAPT with duration lasting from 1 to 3 months, the only trial to directly compare 1- to 3-month DAPT was the MASTER-DAPT trial, which found 1-month DAPT to be noninferior to 3-month DAPT with relation to NACE and MACE while also offering a statistically significant reduction in postoperative Oct 9, 2012 · A New Strategy for Discontinuation of Dual Antiplatelet Therapy : The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent To compare this cohort with the 12-month DAPT cohort, we reviewed the ESTROFA-2 study database, already published in 2010. Jan 1, 2019 · A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). As a historical comparison group, we selected the CoCr-EES group in the RESET trial comparing CoCr-EES with sirolimus-eluting stent conducted in 2010, where nearly 90% of patients had continued DAPT at 1-year. Sep 26, 2019 · A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent Mar 5, 2023 · Background: Limited data are available on short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using third-generation drug-eluting stents with ultrathin struts and advanced polymer technology. Material and methods From pooled analysis of three randomized clinical trials (EXCELLENT, IVUS-XPL, RESET), a total of 2,216 patient with ACS undergoing second-generation DES implantation were selected. However, this ischemic benefit was paired with an increased risk in bleeding and possibly subsequent all-cause mortality. The aim of this study was to develop and validate a machine learning model to predict optimal DAPT duration after contemporary drug‐eluting stent Oct 9, 2012 · E-ZES+3-month DAPT was noninferior to the standard therapy with respect to the occurrence of the primary endpoint. Recently, the DAPT (Dual Antiplatelet Therapy) trial demonstrated reduced rates of stent thrombosis and myocardial infarction (MI) with DAPT extended beyond 1 year after DES implantation. We investigated whether 3- to 6-month DAPT was noninferior to 12-month DAPT after implantation of drug-eluting stents with ultrathin struts and advanced polymer technology There has been no previous prospective study evaluating dual antiplatelet therapy (DAPT) duration shorter than 6 months after cobalt-chromium everolimus-eluting stent (CoCr-EES) implantation. Nov 26, 2018 · The RESET trial enrolled 2,117 patients who were randomly assigned in a 1:1 ratio to receive either an Endeavor zotarolimus DES with 3 months of DAPT or a Resolute zotarolimus DES, everolimus DES, or first-generation sirolimus DES with 12 months of DAPT. Mar 24, 2012 · In the RESET trial, as the study is known, Hong and colleagues included patients with stable angina, unstable angina, or acute MI undergoing elective PCI. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). The DAPT trial has included the largest number of patients. Sep 19, 2012 · In patients who received the second generation Endeavor zotarolimus-eluting stent (Medtronic, Santa Rosa, California) in the RESET* Trial, 3 months of DAPT was noninferior to standard therapy (12 months of DAPT with other DES) with respect to the composite endpoint of cardiovascular death, MI, stent thrombosis, bleeding, and target lesion or The RESET trial was the first study evaluating a mandatory DAPT duration of 3 months with a second-generation DES . (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation [RESET]; NCT01145079). Mar 28, 2024 · This systematic review and network meta-analysis investigates the risk of adverse clinical events associated with different durations of dual antiplatelet therapy for older adults after percutaneous coronary intervention. [6] Oct 2, 2012 · Objectives: The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. Each study . Oct 2, 2012 · In the RESET (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation) trial, we compared the safety and efficacy between patients treated with E-ZES+3-month DAPT and patients treated with the standard therapy. Objectives: The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. Patients, 55% of whom had ACS, were randomized in a 1:1 fashion to either an Endeavor ZES with DAPT for 3 months or an EES, Resolute ZES (Medtronic), or SES with DAPT for 12 months. STOPDAPT trial is a prospective multi-center single-arm study evaluating 3-month DAPT duration after CoCr-EE … Oct 9, 2012 · In the RESET (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation) trial, we compared the safety and efficacy between patients treated with E-ZES+3-month DAPT and patients treated with the standard therapy. owej ifemuv nsstpuqc pozzq rcgn fqlo rfoah qdfonvd hbef uxnc